GKOS vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GKOS presents a dichotomy between strong operational growth and extreme valuation. The Piotroski F-Score of 5/9 indicates a stable financial foundation, supported by an exceptional current ratio of 4.69 and very low debt/equity (0.16). However, the company remains unprofitable with a negative profit margin of -36.99% and a staggering forward P/E of 282.75. While revenue growth is robust at 35.7%, the bearish insider sentiment and weak technical trend suggest a disconnect between analyst optimism and internal confidence.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GKOS vs MRK: Head-to-Head Comparison
This page compares Glaukos Corporation (GKOS) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.